Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chitosan + BCG + polysaccharide nucleic acid + ovalbumin
- Development stage
- Preclinical
- Lead developer
- Huzhou First People's Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intraperitoneal
01
Overview
CS-BCG-PSN-OVA is an experimental nanoparticle-based sustained-release vaccine formulation designed for the treatment of bronchial asthma. It combines immunoregulation and allergen-specific desensitization therapies by encapsulating Bacillus Calmette-Guerin polysaccharide nucleic acid (BCG-PSN) and ovalbumin (OVA) within chitosan (CS) nanoparticles. The vaccine aims to correct the Th1/Th2 immune imbalance characteristic of asthma by suppressing Th2 cytokines (IL-4, IL-5) and promoting Th1 (IFN-gamma) and regulatory T cell (Treg) responses (IL-10, CD4+CD25+Foxp3+). Preclinical studies in murine models have demonstrated that this formulation significantly alleviates airway hyperresponsiveness (AHR) and reduces eosinophilic airway inflammation more effectively than its individual components.
- Other names
- CS-BCG-PSN-OVA sustained-release vaccinechitosan nanoparticles loaded with BCG-polysaccharide nucleic acid and ovalbumin
02
Targets
IL-4 (Interleukin 4)IL-5 (Interleukin 5)IL10 (Interleukin-10)IFNG (Interferon gamma)
Beyond the preview
Go deeper on chitosan + BCG + polysaccharide nucleic acid + ovalbumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chitosan + BCG + polysaccharide nucleic acid + ovalbumin.